Skip to main content

Table 1 Definitions of appropriate initial anti-TB drug regimen for primary outcome measurement

From: Impact of a novel molecular TB diagnostic system in patients at high risk of TB mortality in rural South Africa (Uchwepheshe): study protocol for a cluster randomised trial

Case definition* Appropriate initial anti-TB drug regimen
M. tuberculosis susceptible to rifampicin and isoniazid Isoniazid + rifampicin + pyrazinamide + ethambutol
M. tuberculosis with mono-resistance to isoniazid Isoniazid + rifampicin + pyrazinamide + ethambutol
M. tuberculosis with mono-resistance to rifampicin Standardised second-line regimen§ with isoniazid
Multidrug-resistant M. tuberculosis (MDR-TB)† Standardised second-line regimen§
Extensively drug-resistant M. tuberculosis (XDR-TB)† Standardised XDR-TB regimenǁ
  1. * Case definition based on results of MGIT culture + line probe assay + phenotypic DST.
  2. † MDR-TB defined as resistance to rifampicin and isoniazid.
  3. † XDR-TB defined as MDR plus resistance to ofloxacin and kanamycin.
  4. §Standardised regimen according to national guidelines (kanamycin/amikacin + fluoroquinolone + ethionamide + cycloserine/terizidone ± pyrazinamide ± ethambutol) [27].
  5. ǁStandardised regimen according to national guidelines (capreomycin + fluoroquinolone + ethionamide + cycloserine/terizidone + PAS + clofazimine) [27].